
ACXP Stock Forecast & Price Target
ACXP Analyst Ratings
Bulls say
Acurx Pharmaceuticals Inc. is positioned favorably due to recent positive feedback from both the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), ahead of its upcoming Phase 3 trial in adult populations. The company has demonstrated encouraging antimicrobial activity alongside a favorable safety profile for IBZ, enhancing its prospects for successful development. Additionally, the positive opinion from the Pediatric Committee of the EMA on the Pediatric Investigation Plan for IBZ’s use in children signifies strong regulatory support, further bolstering Acurx's potential for advancement in the critical antibiotic market.
Bears say
Acurx Pharmaceuticals Inc. faces significant challenges related to its clinical stage status, which introduces inherent risks associated with drug development timelines and regulatory approvals, potentially hindering revenue generation. The company's focus on a niche market of Gram-positive selective spectrum antibiotics, while addressing pressing health needs, may limit broader market appeal and competitive positioning against established antibiotic therapies. Additionally, the financial outlook is dimmed by uncertainties surrounding funding for ongoing research and development, coupled with the potential for increased operational costs in advancing its product candidates.
This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.
ACXP Analyst Forecast & Price Prediction
Start investing in ACXP
Order type
Buy in
Order amount
Est. shares
0 shares